Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System

See more here


BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018
Investment Capabilities Expanded as Frederick (“Rick”) Jones, M.D., M.B.A., Joins Team 

See more here


UCSF Medical Center selects Bainbridge Health to Support Its Continued Commitment to Medication Safety 

See more here


Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms

See more here


VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens

See more here


Servier and Treventis begin strategic research partnership in neurodegenerative diseases

See more here


VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of its Lead Antibiotic Program 

See more here